Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 151,793 shares of the stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $103.23, for a total value of $15,669,591.39. Following the completion of the transaction, the insider now owns 120,555,804 shares of the company’s stock, valued at approximately $12,444,975,646.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Friday, August 10th, Lilly Endowment Inc sold 3,587 shares of Eli Lilly And Co stock. The stock was sold at an average price of $103.06, for a total value of $369,676.22.
  • On Monday, August 6th, Lilly Endowment Inc sold 195,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $102.15, for a total value of $19,919,250.00.
  • On Thursday, August 2nd, Lilly Endowment Inc sold 190,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $99.58, for a total value of $18,920,200.00.
  • On Tuesday, July 31st, Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $98.74, for a total value of $20,241,700.00.
  • On Tuesday, July 24th, Lilly Endowment Inc sold 185,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $92.03, for a total value of $17,025,550.00.
  • On Thursday, July 5th, Lilly Endowment Inc sold 170,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $86.62, for a total value of $14,725,400.00.
  • On Friday, June 15th, Lilly Endowment Inc sold 180,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $86.65, for a total value of $15,597,000.00.
  • On Wednesday, June 13th, Lilly Endowment Inc sold 11,104 shares of Eli Lilly And Co stock. The stock was sold at an average price of $86.27, for a total value of $957,942.08.
  • On Monday, June 11th, Lilly Endowment Inc sold 51,198 shares of Eli Lilly And Co stock. The stock was sold at an average price of $86.38, for a total value of $4,422,483.24.
  • On Monday, June 4th, Lilly Endowment Inc sold 135,478 shares of Eli Lilly And Co stock. The stock was sold at an average price of $85.13, for a total value of $11,533,242.14.

Eli Lilly And Co stock traded up $1.36 during trading hours on Friday, hitting $105.72. The stock had a trading volume of 150,951 shares, compared to its average volume of 4,272,449. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. The firm has a market capitalization of $109.82 billion, a price-to-earnings ratio of 24.65, a price-to-earnings-growth ratio of 1.70 and a beta of 0.27. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $104.94.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.20. The company had revenue of $6.36 billion for the quarter, compared to analyst estimates of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. Eli Lilly And Co’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.11 earnings per share. sell-side analysts forecast that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, September 10th. Shareholders of record on Wednesday, August 15th will be issued a $0.5625 dividend. This represents a $2.25 annualized dividend and a yield of 2.13%. The ex-dividend date of this dividend is Tuesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.

Several research analysts have issued reports on LLY shares. Credit Suisse Group set a $80.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Sunday, April 22nd. BMO Capital Markets reiterated a “hold” rating and issued a $79.00 price objective on shares of Eli Lilly And Co in a research report on Tuesday, April 24th. ValuEngine cut Eli Lilly And Co from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. Barclays set a $98.00 price objective on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Tuesday, May 22nd. Finally, Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Wednesday, May 23rd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the stock. Eli Lilly And Co has an average rating of “Hold” and a consensus target price of $100.13.

A number of institutional investors have recently bought and sold shares of LLY. Global X Management Co LLC boosted its stake in shares of Eli Lilly And Co by 3.5% during the second quarter. Global X Management Co LLC now owns 20,982 shares of the company’s stock valued at $1,790,000 after acquiring an additional 714 shares during the last quarter. Titus Wealth Management acquired a new stake in shares of Eli Lilly And Co during the second quarter valued at $211,000. Tiedemann Advisors LLC acquired a new stake in shares of Eli Lilly And Co during the second quarter valued at $228,000. Verition Fund Management LLC boosted its stake in shares of Eli Lilly And Co by 264.2% during the second quarter. Verition Fund Management LLC now owns 10,773 shares of the company’s stock valued at $919,000 after acquiring an additional 7,815 shares during the last quarter. Finally, Ashford Capital Management Inc. acquired a new stake in shares of Eli Lilly And Co during the second quarter valued at $214,000. 76.58% of the stock is currently owned by institutional investors.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Technical Analysis

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.